Liposomal cytarabine. Lymphomatous meningitis: No better than standard cytarabine

Prescrire International

Volumn 15, Issue 81, 2006, Pages 11-12

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; LIPOSOME; METHOTREXATE; STEROID; ANTINEOPLASTIC ANTIMETABOLITE; ANTIVIRUS AGENT;

ARACHNOIDITIS; ARTICLE; CANCER CELL; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONFUSION; DEATH; DRUG DOSE REGIMEN; EUROPE; HEADACHE; HEALTH STATUS; HUMAN; MENINGITIS; MENTAL HEALTH; NAUSEA; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PALLIATIVE THERAPY; PROGNOSIS; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME; VOMITING; COMPARATIVE STUDY; PUNCTURE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; CYTARABINE; HUMANS; LIPOSOMES; LYMPHOMA, NON-HODGKIN; MENINGITIS; SPINAL PUNCTURE; TREATMENT OUTCOME;

EID: 31844431658     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. US Food and Drug Administration - Center for Drug Evaluation and Research "Application number NDA 21041 - Medical review" 7 January 1999: 46 pages.
2. Chamberlain MC et al. "Lymphomatous meningitis" Am J Cancer 2002; 1 (16): 423-434.
3. Gustavsson A et al. "A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma" Acta Oncologica 2003; 42 (5-6): 605-619.
4. European Agency of Medicines - CPMP "European Public Assessment Report (EPAR) Depocyteo - Scientific discussion" Rev. 2, posted on the Agency's site on 24 January 2005: 13 pages.
5. Howell SB "Liposomal cytarabine for the treatment of lymphomatous meningitis" Biol Ther Lymphoma 2003; 6 (1): 1-14.
6. Glantz MJ et al. "Randomized trial of a slow-release versus a standard formulation of cytarabine for intrathecal treatment of lymphomatous meningitis" J Clin Oncol 1999; 17 (10): 3110-3116.